Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics' stock has been influenced by several key events in the past six months. The company announced positive topline results from its Phase 2a clinical trial of RAP-219, leading to a substantial pre-market stock surge. Rapport Therapeutics announced the pricing of a public offering of common stock, aiming to generate approximately $250.0 million in gross proceeds. The company reported its Q3 2025 earnings, surpassing analysts' expectations. The stock reached an all-time high closing price of $31.90. Rapport Therapeutics announced the accelerated initiation of its RAP-219 Phase 3 program and an expansion of its epilepsy portfolio. Insider selling transactions were reported by David Bredt and Abraham Ceesay. Wells Fargo initiated coverage of Rapport Therapeutics with an "Overweight" rating, contributing to positive analyst sentiment.

As a clinical-stage biopharmaceutical company, Rapport Therapeutics, Inc. does not currently have commercialized products on the market, therefore, traditional product demand seasonality is not applicable to its current business model. The company's focus is on research, clinical development, and the potential future commercialization of its small molecule precision medicines.

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for central nervous system disorders. The company's core strategy involves its Receptor Associated Protein (RAP) technology platform, which aims to develop precision neuromedicines by targeting specific neuronal receptor complexes. Its lead product candidate is RAP-219, an investigational small molecule designed to inhibit TARPy8-containing AMPARs and is being developed for the treatment of focal epilepsy, peripheral neuropathic pain, and bipolar disorder. The company's pipeline includes RAP-199, another TARPy8-targeted molecule, and nicotinic acetylcholine receptor (nAChR) programs.

Rapport Therapeutics, Inc. is headquartered in Boston, Massachusetts, and has a subsidiary in Massachusetts. While its primary operations are in the U.S., Rapport participates in healthcare and investor conferences in various global locations, indicating a broader engagement in scientific and investor communities.

Rapport Therapeutics has maintained a generally positive brand reputation, primarily driven by promising clinical trial results and positive analyst sentiment. The successful Phase 2a trial of RAP-219 in focal onset seizures has been a key factor in bolstering its reputation. Analysts have issued "Buy" or "Strong Buy" ratings, with an average price target indicating significant upside potential.

Rapport Therapeutics, Inc. has a significant institutional ownership base, with 210 institutional owners holding a total of 51,351,034 shares as of January 30, 2026. Major institutional shareholders include Trv Gp V, Llc, Fmr Llc, Arch Venture Corp, Capital International Investors, Cormorant Asset Management, LP, Goldman Sachs Group Inc, Sofinnova Investments, Inc., Vanguard Group Inc, Johnson & Johnson, and BlackRock, Inc. Individual insider ownership accounts for approximately 4.16% of the shares. Notable individual owners and recent insider transactions include Abraham Ceesay, David Bredt, Swamy Yeleswaram, Steven Paul, Reid Huber, Wendy Young, and Cheryl Gault.